Navigation Links
Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
Date:4/14/2009

LA JOLLA, Calif., April 14 /PRNewswire/ -- Zenobia Therapeutics, Inc., the leader in fragment-based lead discovery for diseases of the central nervous system, announced successful completion of the first phase of its services agreement with Syntonix Pharmaceuticals, a wholly-owned subsidiary of Biogen Idec (Nasdaq: BIIB). As part of the agreement, Syntonix gains access to Zenobia's technology and expertise in structural biology, crystallization and X-ray structure determination. Zenobia completed three unique protein structures during the first five months of the agreement. The agreement includes research funding and milestone payments.

"Syntonix challenged us with a difficult program, and through close collaboration between our scientists, we are pleased to deliver results," said Vicki Nienaber, Ph.D., President, CSO and founder of Zenobia.

The program required dedicated expertise in protein crystallization including specialized techniques and multiple rounds of optimization.

"It was a challenging target to crystallize, with more than 800 conditions being screened followed by careful optimization of multiple parameters, which was a key for successful structure determination," said Vandana Sridhar, head of Zenobia's crystallization group.

Zenobia has rapid access to high-energy synchrotron sources for data collection through an agreement with Shamrock Biostructures, located near the Advanced Photon Source (APS) in Chicago, IL.

"Synchrotron radiation was required for this program, and we are fortunate to have routine access to the only third-generation synchrotron in the U.S. through our agreement with Shamrock," said Dr. Nienaber.

"Having access to these new experimental crystal structures will allow us to more efficiently design and develop our internal drug
'/>"/>

SOURCE Zenobia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
2. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
3. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
4. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
5. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
6. Cell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market
7. TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
8. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
9. Arno Therapeutics Reports 2008 Year-End Financial Results
10. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
11. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ANGELES , Aug. 4, 2015   California ... the recent acquisition of LifeLine Cryogenics, an east coast ... New York tristate area. LifeLine ... and all prepaid contracts will be honored. ... cryogenics services, offering storage of sperm, eggs, embryos, and ...
(Date:8/3/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced ... Annual Canaccord|Genuity Growth Conference in Boston, ... CEO, William C. Taylor , President and COO, ...
(Date:8/3/2015)... Delaware , August 3, 2015 ... in the commercialization of its Bio-electrical Signal Therapy device ... noninvasive treatment of hard to heal chronic wounds, today ... agreement with Chemipal, an Israeli distributor specializing in medical ... device. Chemipal is a 70 years old, ...
(Date:7/31/2015)... July 31, 2015 In today,s fast ... help them drive positive health outcomes, improve profitability ... of patient care in their communities. At ThoughtSpot ... and conference, AmerisourceBergen announced a new set of ... Administration Organization and help independent pharmacies endure the ...
Breaking Biology Technology:FamilyCord Announces Acquisition of LifeLine Cryogenics 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3
... Advanced Instruments, Inc . today introduced the ... automation-friendly osmometer for the biopharmaceutical industry."The ... designed for -- and completely redefines -- automation ... said Kelly Peterson, Product Manager, Advanced Instruments ( ...
... announced today,promising findings on the in vitro ... cancer developed on the basis of its ... both in vitro and in vivo models,Santaris ... inhibition of disease-associated microRNAs due to their ...
... April 20 Psylin Neurosciences Inc., ... Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. announced today ... novel compound, PSN0041, for the treatment of depression.(Logo: ... )PSN0041, a peptide from Amylin,s proprietary polypeptide hormone ...
Cached Biology Technology:Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry 2Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry 3LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs 2Psylin Neurosciences Commences Development of Compound for Depression 2Psylin Neurosciences Commences Development of Compound for Depression 3
(Date:7/27/2015)... July 27, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Huawei has selected the ... for its stylish smartwatch. Huawei chose the state-of-the-art ... low power and highly responsive human interface qualities ... designers also required a classic round watch face ...
(Date:7/21/2015)... Sweden , July 21, 2015 Today, ... FPC1025. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
(Date:7/13/2015)... July 13, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced sampling of ClearPad ® ... driver integration (TDDI) product targeting smartphones and tablets. ... combine Synaptics , best-in-class touch controller IP ... technology developed in the company,s Japan Design Center. ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... In a discovery that seems counterintuitive, a study appearing ... has found that tendons in high-stress and strain ... frequently than low-stress tendons. This study sheds some light ... during aging. Tendons, composed of collagen and other ...
... a defect in cellular pathways that provides a new explanation ... known as craniosynostosis. Mutations of the WNT and ... regulate bone formation at the stem cell level, according to ... Science Signaling . "Our work contributes to the overall ...
... Rensselaer Polytechnic Institute and principal investigator Glenn Monastersky have been ... Stem Cell Science Program (NYSTEM) of the Empire State Stem ... the Center for Biotechnology and Interdisciplinary Studies (CBIS), said the ... excellence for basic stem cell research within the CBIS. ...
Cached Biology News:High-strain tendons repair less frequently 2Stem-cell disruption induces skull deformity, UR study shows 2Rensselaer Polytechnic Institute wins $2.45 million grant to support stem cell research 2
Contains L-glutamine...
... the 11(R)-LOs of the sea urchin, ... hydra, H. vulgaris. The biological activity ... and tentacle regeneration, respectively, in these ... aspirin-treated recombinant COX-2 is incubated with ...
Rabbit anti-T-box 6...
karyopherin alpha2 (2G7)...
Biology Products: